JP6871876B2 - がんを治療するための組成物と方法 - Google Patents

がんを治療するための組成物と方法 Download PDF

Info

Publication number
JP6871876B2
JP6871876B2 JP2017566608A JP2017566608A JP6871876B2 JP 6871876 B2 JP6871876 B2 JP 6871876B2 JP 2017566608 A JP2017566608 A JP 2017566608A JP 2017566608 A JP2017566608 A JP 2017566608A JP 6871876 B2 JP6871876 B2 JP 6871876B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
cells
composition
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017566608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509469A (ja
JP2018509469A5 (https=
Inventor
カリパダ パハン
カリパダ パハン
Original Assignee
ラッシュ ユニヴァーシティ メディカル センター
ラッシュ ユニヴァーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラッシュ ユニヴァーシティ メディカル センター, ラッシュ ユニヴァーシティ メディカル センター filed Critical ラッシュ ユニヴァーシティ メディカル センター
Publication of JP2018509469A publication Critical patent/JP2018509469A/ja
Publication of JP2018509469A5 publication Critical patent/JP2018509469A5/ja
Application granted granted Critical
Publication of JP6871876B2 publication Critical patent/JP6871876B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017566608A 2015-03-11 2016-03-04 がんを治療するための組成物と方法 Active JP6871876B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131343P 2015-03-11 2015-03-11
US62/131,343 2015-03-11
PCT/US2016/020864 WO2016144743A1 (en) 2015-03-11 2016-03-04 Compositions and methods for treating cancer

Publications (3)

Publication Number Publication Date
JP2018509469A JP2018509469A (ja) 2018-04-05
JP2018509469A5 JP2018509469A5 (https=) 2019-04-18
JP6871876B2 true JP6871876B2 (ja) 2021-05-19

Family

ID=56879779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566608A Active JP6871876B2 (ja) 2015-03-11 2016-03-04 がんを治療するための組成物と方法

Country Status (5)

Country Link
US (1) US11279754B2 (https=)
EP (1) EP3268028B1 (https=)
JP (1) JP6871876B2 (https=)
CA (1) CA2979210A1 (https=)
WO (1) WO2016144743A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6871876B2 (ja) 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法
US20230174636A1 (en) * 2020-05-12 2023-06-08 Rush University Medical Center Compositions and methods for treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
MY157915A (en) * 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
WO2012159100A1 (en) * 2011-05-19 2012-11-22 Rush University Medical Center Il-12 p40 monomer, monoclonal antibody against p40 homodimer and the combination of the two for autoimmune disease treatment
JP6871876B2 (ja) 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法

Also Published As

Publication number Publication date
WO2016144743A1 (en) 2016-09-15
EP3268028B1 (en) 2025-05-21
JP2018509469A (ja) 2018-04-05
US11279754B2 (en) 2022-03-22
CA2979210A1 (en) 2016-09-15
EP3268028A4 (en) 2018-09-05
US20180194837A1 (en) 2018-07-12
EP3268028A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
JP7761991B2 (ja) ガイドとして自身のカルレティキュリンを使用して癌細胞を食べるマクロファージ
Wu et al. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models
US11376272B2 (en) Methods of modulating immune activity
JP7133241B2 (ja) Ｉｆｎと抗ｐｄ－ｌ１抗体の融合タンパク質およびその使用
TWI786322B (zh) 免疫療法與ｍｄｍ２抑制劑的組合及其用途
RU2689162C2 (ru) Способы повышения эффективности противоопухолевого иммунного ответа
JP7846960B2 (ja) 好酸球又はマスト細胞関連障害の治療
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
CA3101340A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
HUE027678T2 (en) Tools and Procedures for DLBCL treatment
US20230101029A1 (en) Methods of using il-33 protein in treating cancers
US20220096400A1 (en) Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
JP2023531676A (ja) ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
US11773158B2 (en) Method of treatment of a tumor with an IL-8 antibody
US20220111069A1 (en) Immunoswitch nanoparticles for reprogrammed t cell responses
US20220249621A1 (en) TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
JP6693873B2 (ja) Ｇｄ２陽性がんを処置するための製剤および方法
JP2024509915A (ja) 治療におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合物質
Osorio et al. Intratumoral Fc-optimized agonistic CD40 antibody induces tumor rejection and systemic antitumor immunity in patients with metastatic cancer
JP6871876B2 (ja) がんを治療するための組成物と方法
US20210353749A1 (en) Guanabenz as an adjuvant for immunotherapy
KR20250155054A (ko) 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
JP2024517985A (ja) 抗－ＣＤ３００ｃモノクローナル抗体及びその癌の予防または治療用バイオマーカー
Bharadwaj et al. Recent Developments in the Immunotherapeutic Approaches for Cancer Treatment
HK40115916A (zh) 施用嵌合抗原受体免疫疗法的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210416

R150 Certificate of patent or registration of utility model

Ref document number: 6871876

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250